Vabicaserin

Vabicaserin is a serotonin receptor antagonist that was under development by Pfizer for the treatment of obesity. It reached Phase II clinical trials but was discontinued.

History[edit | edit source]

Vabicaserin was first developed by Pfizer, a multinational pharmaceutical corporation. The drug was intended to be used for the treatment of obesity, a prevalent health issue worldwide. However, despite reaching Phase II clinical trials, the development of Vabicaserin was eventually discontinued.

Mechanism of Action[edit | edit source]

Vabicaserin works by antagonizing the serotonin receptor, specifically the 5-HT2C receptor. This receptor is known to play a significant role in regulating appetite and food intake, making it a potential target for obesity treatments.

Clinical Trials[edit | edit source]

Vabicaserin underwent Phase II clinical trials to assess its safety and efficacy in treating obesity. However, the drug was discontinued before it could reach Phase III trials. The reasons for this discontinuation are not publicly disclosed.

See Also[edit | edit source]

Vabicaserin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.